MRI of prostate stem cell antigen expression in prostate tumors

Nanomedicine

Volumn 7, Issue 5, 2012, Pages 691-703

  Ren, Jing ^a   Zhang, Zhuoli ^a,b   Wang, Fang ^a   Yang, Yong ^a   Liu, Ying ^a   Wei, Guangquan ^a   Yang, Angang ^a   Zhang, Rui ^a   Huan, Yi ^a   Cui, Yali ^c   Larson, Andrew C ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NORTHWEST UNIVERSITY   (China)

Author keywords

imaging probe; magnetic resonance imaging; prostate cancer diagnosis; prostate stem cell antigen

Indexed keywords

GOLD NANOPARTICLE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PROSTATE STEM CELL ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CONTROLLED STUDY; IN VIVO STUDY; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, IMMOBILIZED; ANTIGENS, NEOPLASM; GOLD; GPI-LINKED PROTEINS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METAL NANOPARTICLES; MICE; MOLECULAR IMAGING; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS;

EID: 84861632550     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.147     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009).
2. Lin GA, Aaronson DS, Knight SJ, Carroll PR, Dudley RA. Patient decision aids for prostate cancer treatment: a systematic review of the literature. CA Cancer J. Clin. 59(6), 379-390 (2009).
3. De Visschere P, Oosterlinck W, De Meerleer G, Villeirs G. Clinical and imaging tools in the early diagnosis of prostate cancer, a review. JBR-BTR 93(2), 62-70 (2010).
4. Mitterberger M, Horninger W, Aigner F et al. Ultrasound of the prostate. Cancer Imaging 10, 40-48 (2010).
5. Ukimura O. Evolution of precise and multimodal MRI and TRUS in detection and management of early prostate cancer. Expert Rev. Med. Devices 7(4), 541-554 (2010).
6. Turkbey B, Albert PS, Kurdziel K, Choyke PL. Imaging localized prostate cancer: current approaches and new developments. AJR Am. J. Roentgenol. 192(6), 1471-1480 (2009).
7. Beissert M, Lorenz R, Gerharz EW. Rational imaging in locally advanced prostate cancer. Urologe A 47(11), 1405-1416 (2008).
8. Augustin H, Fritz GA, Ehammer T, Auprich M, Pummer K. Accuracy of 3-Tesla magnetic resonance imaging for the staging of prostate cancer in comparison to the Partin tables. Acta Radiol. 50(5), 562-569 (2009).
9. Zhao Z, Liu J, Li S, Shen W. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia. Prostate 69(12), 1292-1302 (2009).
10. Giovacchini G, Picchio M, Scattoni V et al. PSA doubling time for prediction of [(11)C] choline PET/CT fndings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging 37(6), 1106-1116 (2010).
11. Lapi SE, Wahnishe H, Pham D et al. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specifc membrane antigen-targeted imaging agent for prostate cancer. J. Nucl. Med. 50(12), 2042-2048 (2009).
12. Turkbey B, Pinto PA, Choyke PL. Imaging techniques for prostate cancer: implications for focal therapy. Nat. Rev. Urol. 6(4), 191-203 (2009).
13. Eyal E, Bloch BN, Rofsky NM et al. Principal component ana lysis of dynamic contrast enhanced MRI in human prostate cancer. Invest. Radiol. 45(4), 174-181 (2010).
14. Huang HC, Chang PY, Chang K et al. Formulation of novel lipid-coated magnetic nanoparticles as the probe for in vivo imaging. J. Biomed. Sci. 16, 86 (2009).
15. Li Z, Jian L, Wang H, Cui Y. Flow injection chemiluminescent determination of clenbuterol using GoldMag particles as carrier. Food Addit. Contam. 24(1), 21-25 (2007). (Pubitemid 44911868)
16. Islam T, Josephson L. Current state and future applications of active targeting in malignancies using superparamagnetic iron oxide nanoparticles. Cancer Biomark. 5(2), 99-107 (2009).
17. Thorek DL, Tsao PY, Arora V, Zhou L, Eisenberg RA, Tsourkas A. In vivo, multimodal imaging of B cell distribution and response to antibody immunotherapy in mice. PLoS ONE 5(5), e10655 (2010).
18. Farrell E, Wielopolski P, Pavljasevic P et al. Cell labelling with superparamagnetic iron oxide has no effect on chondrocyte behaviour. Osteoarthritis Cartilage 17(7), 961-967 (2009).
19. Long CM, Van Laarhoven HW, Bulte JW, Levitsky HI. Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes. Cancer Res. 69(7), 3180-3187 (2009).
20. Joung JY, Cho KS, Kim JE et al. Prostate stem cell antigen mRNA in peripheral blood as a potential predictor of biochemical recurrence in high-risk prostate cancer. J. Surg. Oncol. 101(2), 145-148 (2010).
21. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specifc membrane antigen. Semin. Oncol. 30(5), 667-676 (2003).
22. Raff AB, Gray A, Kast WM. Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett. 277(2), 126-132 (2009).
23. Reiter RE, Gu Z, Watabe T et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl Acad. Sci. USA 95(4), 1735-1740 (1998). (Pubitemid 28103463)
24. Chao X, Guo L, Zhao Y et al. PEG-modifed GoldMag nanoparticles (PGMNs) combined with the magnetic feld for local drug delivery J. Drug Target. 19(3), 161-170 (2011).
25. Chao X, Shi F, Zhao YY et al. Cytotoxicity of FeO/Au composite nanoparticles loaded with doxorubicin combined with magnetic feld. Pharmazie 65(7), 500-504 (2010).
26. Cui Y, Wang Y, Hui W, Zhang Z, Xin X, Chen C. The synthesis of GoldMag nano-particles and their application for antibody immobilization. Biomed. Microdevices 7(2), 153-156 (2005). (Pubitemid 40867914)
27. Wang X, Tao G, Meng Y A novel CdSe/CdS quantum dot-based competitive fuoroimmunoassay for the detection of clenbuterol residue in pig urine using magnetic core/shell FeO/Au nanoparticles as a solid carrier. Anal. Sci. 25(12), 1409-1413 (2009).
28. Wang J, Sun Y, Wang L, Zhu X, Zhang H, Song D. Surface plasmon resonance biosensor based on FeO/Au nanocomposites. Colloids Surf. B Biointerfaces 81(2), 600-606 (2010).
29. Schoffelen R, Van Der Graaf WT, Franssen G et al. Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice. J. Nucl. Med. 51(11), 1780-1787 (2010).
30. Schmid I, Uittenbogaart C, Jamieson BD. Live-cell assay for detection of apoptosis by dual-laser fow cytometry using Hoechst 33342 and 7-amino-actinomycin D. Nat. Protoc. 2(1), 187-190 (2007). (Pubitemid 47040082)
31. Kobayashi H, Longmire MR, Ogawa M, Choyke PL, Kawamoto S. Multiplexed imaging in cancer diagnosis: applications and future advances. Lancet Oncol. 11(6), 589-595 (2010).
32. Alford R, Ogawa M, Choyke PL, Kobayashi H. Molecular probes for the in vivo imaging of cancer. Mol. Biosyst. 5(11), 1279-1291 (2009).
33. Emonds KM, Swinnen JV, Mortelmans L, Mottaghy FM. Molecular imaging of prostate cancer. Methods 48(2), 193-199 (2009).
34. Bulte J W, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 17(7), 484-499 (2004). (Pubitemid 39549426)
35. Sun R, Dittrich J, Le-Huu M et al. Physical and biological characterization of superparamagnetic iron oxide-and ultrasmall superparamagnetic iron oxide-labeled cells: a comparison. Invest. Radiol. 40(8), 504-513 (2005). (Pubitemid 41040687)
36. Mowat P, Franconi F, Chapon C et al. Evaluating SPIO-labelled cell MR effciency by three-dimensional quantitative T2* MRI. NMR Biomed. 20(1), 21-27 (2007). (Pubitemid 46335553)
37. Liu G, Wang Z, Lu J et al. Low molecular weight alkyl-polycation wrapped magnetite nanoparticle clusters as MRI probes for stem cell labeling and in vivo imaging. Biomaterials 24, 24 (2010).
38. Kinoshita M, Yoshioka Y, Okita Y, Hashimoto N, Yoshimine T. MR molecular imaging of HER-2 in a murine tumor xenograft by SPIO labeling of anti-HER-2 affbody. Contrast Media Mol. Imaging 5(1), 18-22 (2010).
39. Kumar M, Yigit M, Dai G, Moore A, Medarova Z. Image-guided breast tumor therapy using a small interfering RNA nanodrug. Cancer Res. 70(19), 7553-7561 (2010).
40. Tang D, Yuan R, Chai Y. Magneto-controlled bioelectronics for the antigen-antibody interaction based on magnetic-core/gold-shell nanoparticles functionalized biomimetic interface. Bioprocess Biosyst. Eng. 31(2), 55-61 (2008).
41. Wang C, Chen J, Talavage T, Irudayaraj J. Gold nanorod/Fe3O4 nanoparticle "nano-pearl-necklaces" for simultaneous targeting, dual-mode imaging, and photothermal ablation of cancer cells. Angew. Chem. Int. Ed. Engl. 48(15), 2759-2763 (2009).
42. Chithrani DB. Nanoparticles for improved therapeutics and imaging in cancer therapy. Recent Pat. Nanotechnol. 4(3), 171-180 (2010).
43. Lepin EJ, Leyton JV, Zhou Y et al. An affnity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur. J. Nucl. Med. Mol. Imaging 37(8), 1529-1538 (2010).
44. Olafsen T, Gu Z, Sherman MA et al. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J. Immunother. 30(4), 396-405 (2007). (Pubitemid 46684429)
45. Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J. Clin. Oncol. 28(28), 4390-4399 (2010).
46. Olson WC, Heston WD, Rajasekaran AK. Clinical trials of cancer therapies targeting prostate-specifc membrane antigen. Rev. Recent Clin. Trials 2(3), 182-190 (2007). (Pubitemid 47554839)
47. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat. Rev. Immunol. 10(8), 580-593 (2010).